Search

Your search keyword '"Brochet, Bruno"' showing total 697 results
Start Over Author "Brochet, Bruno"
697 results on '"Brochet, Bruno"'

4. Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension

Author

Hauser, Stephen L, Kappos, Ludwig, Arnold, Douglas L, Bar-Or, Amit, Brochet, Bruno, Naismith, Robert T, Traboulsee, Anthony, Wolinsky, Jerry S, Belachew, Shibeshih, Koendgen, Harold, Levesque, Victoria, Manfrini, Marianna, Model, Fabian, Hubeaux, Stanislas, Mehta, Lahar, and Montalban, Xavier

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Neurosciences, Brain Disorders, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Neurological, Adult, Antibodies, Monoclonal, Humanized, Brain, Female, Follow-Up Studies, Humans, Immunologic Factors, Magnetic Resonance Imaging, Male, Multiple Sclerosis, Relapsing-Remitting, Neuroimaging, Randomized Controlled Trials as Topic, Recurrence, Time Factors, Treatment Outcome, Cognitive Sciences, Neurology & Neurosurgery, Clinical sciences
Abstract

ObjectiveTo assess over 3 years of follow-up the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE) phase of the pooled OPERA: I/II studies in relapsing multiple sclerosis.MethodsAfter 2 years of double-blind, controlled treatment, patients continued OCR (600 mg infusions every 24 weeks) or switched from interferon (IFN)-β-1a (44 μg 3 times weekly) to OCR when entering the OLE phase (3 years). Adjusted annualized relapse rate, time to onset of 24-week confirmed disability progression (CDP)/improvement (CDP), brain MRI activity (gadolinium-enhanced and new/enlarging T2 lesions), and percentage brain volume change were analyzed.ResultsOf patients entering the OLE phase, 88.6% completed year 5. The cumulative proportion with 24-week CDP was lower in patients who initiated OCR earlier vs patients initially receiving IFN-β-1a (16.1% vs 21.3% at year 5; p = 0.014). Patients continuing OCR maintained and those switching from IFN-β-1a to OCR attained near complete and sustained suppression of new brain MRI lesion activity from years 3-5. Over the OLE phase, patients continuing OCR exhibited less whole brain volume loss from double-blind study baseline vs those switching from IFN-β-1a (-1.87% vs -2.15% at year 5; p < 0.01). Adverse events were consistent with past reports and no new safety signals emerged with prolonged treatment.ConclusionCompared with patients switching from IFN-β-1a, earlier and continuous OCR treatment up to 5 years provided sustained benefit on clinical and MRI measures of disease progression.Classification of evidenceThis study provides Class III evidence that earlier and continuous treatment with OCR provided sustained benefit on clinical and MRI outcomes of disease activity and progression compared with patients switching from IFN-β-1a. The study is rated Class III because of the initial treatment randomization disclosure that occurred after inclusion in OLE.Clinical trial identifiersNCT01247324/NCT01412333.

Published
2020

5. Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-naive Patients with High-activity, Early-stage Relapsing-remitting Multiple Sclerosis in the ENSEMBLE Study (P10-6.007)

Author

Vollmer, Timothy, primary, Bermel, Robert, additional, Brochet, Bruno, additional, Berger, Thomas, additional, Carroll, William, additional, Freedman, Mark, additional, Holmoy, Trygve, additional, Karabudak, Rana, additional, Killestein, Joep, additional, Nos, Carlos, additional, Patti, Francesco, additional, Vanopdenbosch, Ludo, additional, Kuenzel, Thomas, additional, Kadner, Karen, additional, Kulyk, Inessa, additional, and Hartung, Hans-Peter, additional

Published
2024
Full Text
View/download PDF

6. Faible activité de la maladie après un traitement de 4 ans par ocrelizumab (OCR) chez des patients naïfs de traitement atteints de sclérose en plaques récurrente-rémittente (SEP-RR) à un stade précoce ; données de l’étude de phase IIIb ensemble

Author

Brochet, Bruno, primary, Patti, Francesco, additional, Bermel, Robert, additional, Berger, Thomas, additional, Carroll, William-M., additional, Holmøy, Trygve, additional, and Karabudak, Rana, additional

Published
2024
Full Text
View/download PDF

10. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

Author

Wolinsky, Jerry S, Arnold, Douglas L, Brochet, Bruno, Hartung, Hans-Peter, Montalban, Xavier, Naismith, Robert T, Manfrini, Marianna, Overell, James, Koendgen, Harold, Sauter, Annette, Bennett, Iain, Hubeaux, Stanislas, Kappos, Ludwig, and Hauser, Stephen L

Published
2020
Full Text
View/download PDF

14. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study

Author

Brochet, Bruno, primary, Solari, Alessandra, additional, Lechner-Scott, Jeannette, additional, Piehl, Fredrik, additional, Langdon, Dawn, additional, Hupperts, Raymond, additional, Selmaj, Krzysztof, additional, Patti, Francesco, additional, Brieva, Luis, additional, Maida, Eva Maria, additional, Alexandri, Nektaria, additional, Smyk, Andrzej, additional, Nolting, Axel, additional, Keller, Birgit, additional, Montalban, Xavier, additional, and Kubala Havrdova, Eva, additional

Published
2023
Full Text
View/download PDF

15. Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data

Author

Thurin, Nicolas H., Bosco-Levy, Pauline, Blin, Patrick, Rouyer, Magali, Jové, Jérémy, Lamarque, Stéphanie, Lignot, Séverine, Lassalle, Régis, Abouelfath, Abdelilah, Bignon, Emmanuelle, Diez, Pauline, Gross-Goupil, Marine, Soulié, Michel, Roumiguié, Mathieu, Le Moulec, Sylvestre, Debouverie, Marc, Brochet, Bruno, Guillemin, Francis, Louapre, Céline, Maillart, Elisabeth, Heinzlef, Olivier, Moore, Nicholas, and Droz-Perroteau, Cécile

Published
2021
Full Text
View/download PDF

18. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

Author

Beecham, Ashley, Patsopoulos, Nikolaos, Xifara, Dionysia, Davis, Mary, Kemppinen, Anu, Cotsapas, Chris, Shah, Tejas, Spencer, Chris, Booth, David, Goris, An, Oturai, Annette, Saarela, Janna, Fontaine, Bertrand, Hemmer, Bernhard, Martin, Claes, Zipp, Frauke, DAlfonso, Sandra, Martinelli-Boneschi, Filippo, Taylor, Bruce, Harbo, Hanne, Kockum, Ingrid, Hillert, Jan, Olsson, Tomas, Ban, Maria, Barizzone, Nadia, Barrett, Jeffrey, Bellenguez, Céline, Bergamaschi, Laura, Bernardinelli, Luisa, Berthele, Achim, Biberacher, Viola, Binder, Thomas, Blackburn, Hannah, Bomfim, Izaura, Brambilla, Paola, Broadley, Simon, Brochet, Bruno, Brundin, Lou, Buck, Dorothea, Butzkueven, Helmut, Caillier, Stacy, Camu, William, Carpentier, Wassila, Cavalla, Paola, Celius, Elisabeth, Coman, Irène, Comi, Giancarlo, Corrado, Lucia, Cosemans, Leentje, Cournu-Rebeix, Isabelle, Cusi, Daniele, Damotte, Vincent, Defer, Gilles, Delgado, Silvia, Deloukas, Panos, di Sapio, Alessia, Dilthey, Alexander, Donnelly, Peter, Dubois, Bénédicte, Duddy, Martin, Edkins, Sarah, Elovaara, Irina, Esposito, Federica, Evangelou, Nikos, Fiddes, Barnaby, Field, Judith, Franke, Andre, Freeman, Colin, Frohlich, Irene, Galimberti, Daniela, Gieger, Christian, Graetz, Christiane, Graham, Andrew, Grummel, Verena, Guaschino, Clara, Hadjixenofontos, Athena, Hakonarson, Hakon, Halfpenny, Christopher, Hall, Gillian, Hall, Per, Hamsten, Anders, Harley, James, Harrower, Timothy, Hawkins, Clive, Hellenthal, Garrett, Hillier, Charles, Hobart, Jeremy, Hoshi, Muni, Hunt, Sarah, Jagodic, Maja, Jelčić, Ilijas, Jochim, Angela, Kendall, Brian, Kermode, Allan, Kilpatrick, Trevor, Koivisto, Keijo, Konidari, Ioanna, Korn, Thomas, Kronsbein, Helena, and Langford, Cordelia

Subjects
Chromosome Mapping, Gene Frequency, Genetic Loci, Genetic Predisposition to Disease, Genetic Variation, Genome-Wide Association Study, Genotype, Humans, Multiple Sclerosis, Polymorphism, Single Nucleotide, White People
Abstract

Using the ImmunoChip custom genotyping array, we analyzed 14,498 subjects with multiple sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 potentially associated regions (P < 1.0 × 10(-4)). In a replication phase, we combined these data with previous genome-wide association study (GWAS) data from an independent 14,802 subjects with multiple sclerosis and 26,703 healthy controls. In these 80,094 individuals of European ancestry, we identified 48 new susceptibility variants (P < 5.0 × 10(-8)), 3 of which we found after conditioning on previously identified variants. Thus, there are now 110 established multiple sclerosis risk variants at 103 discrete loci outside of the major histocompatibility complex. With high-resolution Bayesian fine mapping, we identified five regions where one variant accounted for more than 50% of the posterior probability of association. This study enhances the catalog of multiple sclerosis risk variants and illustrates the value of fine mapping in the resolution of GWAS signals.

Published
2013

19. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

Author

International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham, Ashley H, Patsopoulos, Nikolaos A, Xifara, Dionysia K, Davis, Mary F, Kemppinen, Anu, Cotsapas, Chris, Shah, Tejas S, Spencer, Chris, Booth, David, Goris, An, Oturai, Annette, Saarela, Janna, Fontaine, Bertrand, Hemmer, Bernhard, Martin, Claes, Zipp, Frauke, D'Alfonso, Sandra, Martinelli-Boneschi, Filippo, Taylor, Bruce, Harbo, Hanne F, Kockum, Ingrid, Hillert, Jan, Olsson, Tomas, Ban, Maria, Oksenberg, Jorge R, Hintzen, Rogier, Barcellos, Lisa F, Wellcome Trust Case Control Consortium 2 (WTCCC2), International IBD Genetics Consortium (IIBDGC), Agliardi, Cristina, Alfredsson, Lars, Alizadeh, Mehdi, Anderson, Carl, Andrews, Robert, Søndergaard, Helle Bach, Baker, Amie, Band, Gavin, Baranzini, Sergio E, Barizzone, Nadia, Barrett, Jeffrey, Bellenguez, Céline, Bergamaschi, Laura, Bernardinelli, Luisa, Berthele, Achim, Biberacher, Viola, Binder, Thomas MC, Blackburn, Hannah, Bomfim, Izaura L, Brambilla, Paola, Broadley, Simon, Brochet, Bruno, Brundin, Lou, Buck, Dorothea, Butzkueven, Helmut, Caillier, Stacy J, Camu, William, Carpentier, Wassila, Cavalla, Paola, Celius, Elisabeth G, Coman, Irène, Comi, Giancarlo, Corrado, Lucia, Cosemans, Leentje, Cournu-Rebeix, Isabelle, Cree, Bruce AC, Cusi, Daniele, Damotte, Vincent, Defer, Gilles, Delgado, Silvia R, Deloukas, Panos, di Sapio, Alessia, Dilthey, Alexander T, Donnelly, Peter, Dubois, Bénédicte, Duddy, Martin, Edkins, Sarah, Elovaara, Irina, Esposito, Federica, Evangelou, Nikos, Fiddes, Barnaby, Field, Judith, Franke, Andre, Freeman, Colin, Frohlich, Irene Y, Galimberti, Daniela, Gieger, Christian, Gourraud, Pierre-Antoine, Graetz, Christiane, Graham, Andrew, Grummel, Verena, Guaschino, Clara, Hadjixenofontos, Athena, Hakonarson, Hakon, Halfpenny, Christopher, Hall, Gillian, Hall, Per, Hamsten, Anders, Harley, James, and Harrower, Timothy

Subjects
International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, International IBD Genetics Consortium, Humans, Multiple Sclerosis, Genetic Predisposition to Disease, Chromosome Mapping, Gene Frequency, Genotype, Polymorphism, Single Nucleotide, Genetic Variation, Genome-Wide Association Study, Genetic Loci, White People, Neurosciences, Prevention, Autoimmune Disease, Genetics, Brain Disorders, Human Genome, Neurodegenerative, Aetiology, 2.1 Biological and endogenous factors, Inflammatory and immune system, Biological Sciences, Medical and Health Sciences, Developmental Biology
Abstract

Using the ImmunoChip custom genotyping array, we analyzed 14,498 subjects with multiple sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 potentially associated regions (P < 1.0 × 10(-4)). In a replication phase, we combined these data with previous genome-wide association study (GWAS) data from an independent 14,802 subjects with multiple sclerosis and 26,703 healthy controls. In these 80,094 individuals of European ancestry, we identified 48 new susceptibility variants (P < 5.0 × 10(-8)), 3 of which we found after conditioning on previously identified variants. Thus, there are now 110 established multiple sclerosis risk variants at 103 discrete loci outside of the major histocompatibility complex. With high-resolution Bayesian fine mapping, we identified five regions where one variant accounted for more than 50% of the posterior probability of association. This study enhances the catalog of multiple sclerosis risk variants and illustrates the value of fine mapping in the resolution of GWAS signals.

Published
2013

20. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Author

Bartholomé, Emmanuel, D'Hooghe, Marie, Pandolfo, Massimo, Van Wijmeersch, Bart, Bhan, Virender, Blevins, Gregg, Brunet, Donald, Devonshire, Virginia, Duquette, Pierre, Freedman, Mark, Grand'Maison, François, Jacques, François, Lapierre, Yves, Lee, Liesly, Morrow, Sarah, Yeung, Michael, Dufek, Michal, Havrdová, Eva Kubala, Kanovsky, Petr, Stetkarova, Ivana, Talabova, Marika, Frederiksen, Jette, Kant, Matthias, Petersen, Thor, Ravnborg, Mads, Sellebjerg, Finn, Airas, Laura, Elovaara, Irina, Eralinna, Juha-Pekka, Sarasoja, Taneli, Al Khedr, Abdullatif, Brassat, David, Brochet, Bruno, Camu, William, Debouverie, Marc, Laplaud, David, Lebrun Frenay, Christine, Pelletier, Jean, Vermersch, Patrick, Vukusi, Sandra, Baum, Karl, Berthele, Achim, Faiss, Juergen, Flachenecker, Peter, Hohlfeld, Reinhard, Krumbholz, Markus, Lassek, Christoph, Maeurer, Mathias, Meuth, Sven, Ziemssen, Tjalf, Hardiman, Orla, McGuigan, Christopher, Achiron, Anat, Karussis, Dimitrios, Bergamaschi, Roberto, Morra, Vincenzo Brescia, Comi, Giancarlo, Cottone, Salvatore, Grimaldi, Luigi, Mancardi, Giovanni Luigi, Massacesi, Luca, Nocentini, Ugo, Salvetti, Marco, Scarpini, Elio, Sola, Patrizia, Tedeschi, Gioacchino, Trojano, Maria, Zaffaroni, Mauro, Frequin, Stephan, Hupperts, Raymond, Killestein, Joep, Schrijver, Hans, Van Dijl, Ronald, van Munster, Erik, Czarnecki, Maciej, Drozdowski, Wieslaw, Fryze, Waldemar, Hertmanowska, Hanka, Ilkowski, Jan, Kaminska, Anna, Klodowska-Duda, Gabriela, Maciejowski, Maciej, Motta, Ewa, Podemski, Ryszard, Potemkowski, Andrzej, Rog, Teresa, Selmaj, Krzysztof, Stelmasiak, Zbigniew, Stepien, Adam, Tutaj, Andrzej, Zaborski, Jacek, Boyko, Alexey, Chefranova, Zanna, Evdoshenko, Evgeny, Khabirov, Farit, Sivertseva, Stella, Yakupov, Eduard, Alvarez Cermeño, Jose Carlos, Escartin, Antonio, Fernandez, Oscar Fernandez, Garcia-Merino, Antonio, Hernandez Perez, Miguel Angel, Ayuso, Guillermo Izquierdo, Lallana, José Meca, Gairin, Xavier Montalban, Oreja-Guevara, Celia, Saiz Hinarejos, Albert, Gunnarsson, Martin, Lycke, Jan, Martin, Claes, Piehl, Fredrik, Roshanisefat, Homayoun, Sundstrom, Peter, Duddy, Martin, Gran, Bruno, Harrower, Timothy, Hobart, Jeremy, Kapoor, Raju, Lee, Martin, Mattison, Paul, Nicholas, Richard, Pearson, Owen, Rashid, Waqar, Rog, David, Sharrack, Basil, Silber, Eli, Turner, Ben, Williams, Anna, Woolmore, John, Young, Carolyn, Bandari, Daniel, Berger, Joseph, Camac, Ann, Cohan, Stanley, Conway, Jill, Edwards, Keith, Fabian, Michelle, Florin, Jack, Freedman, Steven, Garwacki, Dennis, Goldman, Myla, Harrison, Daniel, Herrman, Craig, Huang, Deren, Javed, Adil, Jeffery, Douglas, Kamin, Stephen, Katsamakis, George, Khatri, Bhupendra, Langer-Gould, Annette, Lynch, Sharon, Mattson, David, Miller, Tamara, Miravalle, Augusto, Moses, Harold, Muley, Suraj, Napier, James, Nielsen, Allen, Pachner, Andrew, Pardo, Gabriel, Picone, MaryAnn, Robertson, Derrick, Royal, Walter, Sheppard, Christopher, Thrower, Ben, Twyman, Cary, Waubant, Emmanuelle, Wendt, Jeanette, Yadav, Vijayshree, Zabad, Rana, Zarelli, Greg, Ho, Pei-Ran, Campbell, Nolan, Chang, Ih, Deykin, Aaron, Forrestal, Fiona, Lucas, Nisha, Yu, Bei, Arnold, Douglas L, Freedman, Mark S, Goldman, Myla D, Hartung, Hans-Peter, Miller, Aaron, Cadavid, Diego, Mikol, Dan, and Steiner, Deborah

Published
2018
Full Text
View/download PDF

27. Infusion-Related Reactions With Ocrelizumab: Risk Factors, Symptom Management and Patient Choices in the ENSEMBLE PLUS Study (P7-3.003)

Author

Bermel, Robert, primary, Killestein, Joep, additional, Berger, Thomas, additional, Brochet, Bruno, additional, Carroll, William, additional, Freedman, Mark, additional, Holmoy, Trygve, additional, Karabudak, Rana, additional, Nos, Carlos, additional, Patti, Francesco, additional, Ross, Amy Perrin, additional, Vanopdenbosch, Ludo, additional, Vollmer, Timothy, additional, Buffels, Regine, additional, Kadner, Karen, additional, Bortolami, Oscar, additional, and Hartung, Hans-Peter, additional

Published
2023
Full Text
View/download PDF

28. Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study (S46.004)

Author

Bermel, Robert, primary, Hartung, Hans-Peter, additional, Brochet, Bruno, additional, Benedict, Ralph, additional, Berger, Thomas, additional, Carroll, William, additional, Vollmer, Timothy, additional, Holmoy, Trygve, additional, Karabudak, Rana, additional, Killestein, Joep, additional, Nos, Carlos, additional, Patti, Francesco, additional, Ross, Amy Perrin, additional, Vanopdenbosch, Ludo, additional, Wuerfel, Jens, additional, Kuenzel, Thomas, additional, Kadner, Karen, additional, Kulyk, Inessa, additional, and Freedman, Mark, additional

Published
2023
Full Text
View/download PDF

31. The radiologically isolated syndrome: revised diagnostic criteria

Author

Lebrun-Frénay, Christine, Okuda, Darin, Siva, Aksel, Landes-Chateau, Cassandre, Azevedo, Christina, Mondot, Lydiane, Carra-Dallière, Clarisse, Zephir, Helene, Louapre, Celine, Durand-Dubief, Françoise, Le Page, Emmanuelle, Bensa, Caroline, Ruet, Aurélie, Ciron, Jonathan, Laplaud, David, Casez, Olivier, Mathey, Guillaume, de Seze, Jerome, Zeydan, Burcu, Makhani, Naila, Tutuncu, Melih, Levraut, Michael, Cohen, Mikael, Thouvenot, Eric, Pelletier, Daniel, Kantarci, Orhun, Sehaki, Sabrina, Devys-Meyer, Nathalie, Bereau, Mathieu, Cappe, Chrystelle, Brochet, Bruno, Ouallet, Jean-Christophe, Kounkou, Katy-Kim, Defer, Gilles, Branger, Pierre, Taithe, Frédéric, Dumont, Emilie, Lescieux, Edwige, Fromont, Agnès, Protin, Alexia, Kane, Maty Diop, Hautecoeur, Patrick, Outteryck, Olivier, Vermersch, Patrick, Boucher, Julie, Petit, Julie, Kasonde, Irène Tabellah, de Vilmarrest, Aymeric, Magy, Laurent, Nicol, Marie, Malbezin, Muriel, Olaiz, Javier, Rigaud-Bully, Claire, Debard, Nadine, Cotton, Sandra Vukusic François, Ionescu, Iuliana, Abdelalli, Amalle, Pelletier, Jean, Audoin, Bertrand, Maarouf, Adil, Di Lelio, Bernadette, Ayrignac, Xavier, Labauge, Pierre, Pinna, Frédéric, Guillemin, Francis, Debouverie, Marc, Ziegler, Amandine, Wiertlevski, Sandrine, Bresch, Saskia, Callier, Céline, David, Elodie, Castelnovo, Giovanni, Papeix, Caroline, Maillart, Elisabeth, Lubetzki, Catherine, Zehrouni, Karima, Fontaine, Bertrand, Giannesini, Claire, Hodel, Jérôme, Wahab, Abir, Zedet, Mickaël, Fagniez, Ombeline, Laage, Clémence, Pottier, Corinne, Slesari, Iuliana, Sampaio, Mathilde, Rabois, Emilie, Castex, Cédric, Hebant, Benjamin, Guillaume, Maxime, Vimont, Christine, Gout, Olivier, Guegen, Antoine, Michel, Laure, Muraz, Romain, Le Port, Damien, Leray, Emmanuelle, Henry, Carole, de Broucker, Thomas, Collongues, Nicolas, Berthe, Carole, Biotti, Damien, Freitas, Noellie, Visneux, Vincent, Forestier, Mélanie, Beltran, Stéphane, Meunier, Géraldine, Servan, Jérôme, Pico, Fernando, Chatagner, Virginie, Radji, Fatai, Morel, Nathalie, Grosset-Jeannin, Deborah, Ungureanu, Aurelian, Boyer, Latine, Suchet, Laurent, Lebrun-Frenay, Christine, Centre Hospitalier Universitaire de Nice (CHU Nice), Université Côte d'Azur (UCA), Unité de Recherche Clinique de la Côte d’Azur (URRIS UR2CA), Centre Hospitalier Universitaire de Nice (CHU Nice)-Université Côte d'Azur (UCA), University of Texas Southwestern Medical Center [Dallas], Cerrahpasa Faculty of Medicine, Istanbul University, University of Southern California (USC), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Lille, Lille Neurosciences & Cognition - U 1172 (LilNCog), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU), Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL], Hospices Civils de Lyon (HCL), CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Fondation Ophtalmologique Adolphe de Rothschild [Paris], Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale (U1215 Inserm - UB), Université de Bordeaux (UB)-Institut François Magendie-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux], Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CIC Plurithématique de Nantes, Institut National de la Santé et de la Recherche Médicale (INSERM)-Ministère des Affaires sociales et de la Santé-Direction générale de l'offre de soins (DGOS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology (U1064 Inserm - CR2TI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Translational Research in Autoimmunity and Inflammation Group (TIMC-T-RAIG), Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 (TIMC ), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA), Centre Hospitalier Universitaire [Grenoble] (CHU), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Adaptation, mesure et évaluation en santé. Approches interdisciplinaires (APEMAC), Université de Lorraine (UL), CHU Strasbourg, CIC Strasbourg (Centre d’Investigation Clinique Plurithématique (CIC - P) ), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nouvel Hôpital Civil de Strasbourg-Hôpital de Hautepierre [Strasbourg], Mayo Clinic [Rochester], Yale School of Medicine [New Haven, Connecticut] (YSM), Service de Neurologie [CHU Nimes] (Pôle NIRR), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut de Génomique Fonctionnelle (IGF), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), and None

Subjects
[SCCO.NEUR]Cognitive science/Neuroscience, diagnostic criteria, radiologically isolated syndrome, Neurology (clinical), prognosis, multiple sclerosis, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, MRI
Abstract

The radiologically isolated syndrome (RIS) was defined in 2009 as the presence of asymptomatic, incidentally identified demyelinating-appearing white matter lesions in the CNS within individuals lacking symptoms typical of multiple sclerosis (MS). The RIS criteria have been validated and predict the transition to symptomatic MS reliably. The performance of RIS criteria that require fewer MRI lesions is unknown. 2009-RIS subjects, by definition, fulfil three to four of four criteria for 2005 dissemination in space (DIS) and subjects fulfilling only one or two lesions in at least one 2017 DIS location were identified within 37 prospective databases. Univariate and multivariate Cox regression models were used to identify predictors of a first clinical event. Performances of different groups were calculated. Seven hundred and forty-seven subjects (72.2% female, mean age 37.7 ± 12.3 years at the index MRI) were included. The mean clinical follow-up time was 46.8 ± 45.4 months. All subjects had focal T2 hyperintensities suggestive of inflammatory demyelination on MRI; 251 (33.6%) fulfilled one or two 2017 DIS criteria (designated as Groups 1 and 2, respectively), and 496 (66.4%) fulfilled three or four 2005 DIS criteria representing 2009-RIS subjects. Group 1 and 2 subjects were younger than the 2009-RIS group and were more likely to develop new T2 lesions over time (P < 0.001). Groups 1 and 2 were similar regarding survival distribution and risk factors for transition to MS. At 5 years, the cumulative probability for a clinical event was 29.0% for Groups 1 and 2 compared to 38.7% for 2009-RIS (P = 0.0241). The presence of spinal cord lesions on the index scan and CSF-restricted oligoclonal bands in Groups 1–2 increased the risk of symptomatic MS evolution at 5 years to 38%, comparable to the risk of development in the 2009-RIS group. The presence of new T2 or gadolinium-enhancing lesions on follow-up scans independently increased the risk of presenting with a clinical event (P < 0.001). The 2009-RIS subjects or Groups 1 and 2 with at least two of the risk factors for a clinical event demonstrated better sensitivity (86.0%), negative predictive value (73.1%), accuracy (59.8%) and area under the curve (60.7%) compared to other criteria studied. This large prospective cohort brings Class I evidence that subjects with fewer lesions than required in the 2009 RIS criteria evolve directly to a first clinical event at a similar rate when additional risk factors are present. Our results provide a rationale for revisions to existing RIS diagnostic criteria.

Published
2023

32. Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study

Author

Papeix, Caroline, Castelnovo, Giovanni, Leray, Emmanuelle, Coustans, Marc, Levy, Pierre, Visy, Jean-Marc, Kobelt, Gisela, Lamy, Fabienne, Allaf, Bashar, Heintzmann, François, Chouette, Isabelle, Raponi, Eric, Durand, Barbara, Grevat, Emmanuelle, Kamar, Driss, Debouverie, Marc, Lebrun-Frenay, Christine, Abdelmoumni, Abdelhakim, Al Aloucy, Mouhmmad Jamal, Al Khedr, Abdullatif, Al Najjar Carpentier, Amer, Alonzo, Bernard, Altarcha, Tony, Ananivi, Amevi, Androdias, Géraldine, Angibaud, Gilles, Artaud-Uriot, Marie-Sylvie, Audry-Chaboud, Dominique, Barre, Marie, Barres, Philippe, Benrabah, Rabah, Berger, Eric, Bergouignan, François-Xavier, Bernady, Patricia, Billy, Christophe, Blanchard, Christian, Bonnan, Mickaël, Borsotti, Jean-Paul, Bossu-van Nieuwenhuyse, Catherine, Bouffeteau, Jean-Claude, Bouillaguet, Sophie, Boukriche, Yassine, Boulesteix, Jean-Marc, Bourre, Bertrand, Brassat, David, Bredin, Alain, Brochet, Bruno, Brugeilles Baguelin, Helene, Camara, Ousmane, Camdessanche, Jean-Philippe, Camu, William, Carel, Christophe, Carlander, Bertrand, Casez, Olivier, Chanel-Soulier, Marie-Pierre, Chapuis, Stéphane, Cimpoesu, Mirella, Ciron, Jonathan, Clavelou, Pierre, Clerc, Christine, Colamarino, Renato, Couratier, Christophe, Courtois, Sylvie, Creange, Alain, Danielli, Antoine, de Broucker, Thomas, de Seze, Jérôme, Defer, Gilles, Delorme, Jérôme, Denis, Béatrice, Derouiche, Fayçal, Devos, Philippe, Deyrolle, Anne-Marie, Dib, Michel, Dib, Joseph, Diot, Eric, Doury, Emmanuelle, Dufourd-Delalande, Sophie, Dupel-Pottier, Corinne, Dussaux, Patrick, Edan, Gilles, Edouard, Thibault, Escaillas, Jean-Pierre, Ferriby, Didier, Fouillet, Nicolas, Fromager, Guillaume, Gaida-Rostane, Tsouria, Gaida, Philippe, Gal, Guillaume, Garrigues, Guillaume, Gayou-Joyeux, Annick, Gentil, Arnaud, Gerard, Philippe, Gere, Julien, Gignoux, Laurence, Girard, Philippe, Giraud, Pierric, Gouttard, Michel, Gras, Pierre, Guennoc, Anne Marie, Gugenheim, Michel, Guilloton, Laurent, Hadjout, Karim, Hautecoeur, Patrick, Hegbe, Yawo, Heinzlef, Olivier, Henry, Patrice, Herve, Yann, Hijazi, Jihad, Homeyer, Pascale, Huttin, Bernard, Ille, Olivier, Jager, Alain, Jomir, Laurentiu, Kardous, Nabil, Kerouanton, Agnès, Kpade, Comlan Paul, Kubler, Christophe, Labauge, Pierre, Lallement, François, Landragin, Nicolas, Laplaud, David Axel, Laribi, Henda, Lavernhe, Gilles, Le Biez, Pierre-Éric, Le Bras, Françoise, Le Coz, Patrick, Leche, Josette, Leder, Sara Julia, Legout, Alain, Levasseur, Michele, Lorenzi-Pernot, Alberta, Louchart, Pierre, Louillet, Fabien, Magy, Laurent, Maillard, Sophie, Maillart, Elisabeth, Maillet-Vioud, Marcel, Mallecourt-Emberger, Catherine, Manchon, Éric, Mania, Alexandre, Martinez-Almoyna, Laurent, Martinez, Mikel, Massengo, Serge, Maugin, Dominique, Medjbeur, Souraya, Meliksetyan, Gayané, Menassa, Michael, Meshaka-Dimitri-Boulos, Dalia, Mick, Gérard, Moreau, Thibault, Moulignier, Antoine, Mourand, Isabelle, Muller, Jean-Philippe, Neuschwander, Philippe, Nibbio, Argentino, Nifle, Chantal, Nkendjuo, Jean-Bertin, Nokam Talom, Ghislain, Ory, Sophie, Patry, Ivania, Pedespan, Bernard, Pelletier, Jean, Pencu, Delia-Gianina, Perrouty, Bruno, Peysson, Stéphane, Popa-Coman, Irène, Pouliquen, André, Prat, Christophe, Prundean, Adriana, Radji, Fataï, Rakotoharinandrasana, Haja Tiana, Razlog, Lilia, Remy, Philippe, Robin, Christophe, Rodier, Gilles, Romero, Jérôme, Roualdes, Brigitte, Rouhart, François, Ruggieri, Irene, Samad, Feras Abdul, Sarafiant, Irina, Schaeffer, Stephane, Schmidt, Nicolas, Schuermans, Philippe, Seiller, Nicolas, Soisson, Thierry, Sortais, Annie, Stankoff, Bruno, Stefanizzi-Debuc, Sabrina, Suchet, Laurent, Tardy, Jean, Taurin, Gregory, Thabuy, Florent, Theaudin, Marie, Tilikete-Froment, Caroline, Tourbah, Ayman, Tourniaire, Patricia, Trefouret, Sylvie, Vastene, Michel, Verdure, Pierre, Vermersch, Patrick, Viala, Frédérique, Videt-Gibou, Dorothée, Vidry, Elisabeth, Vukusic, Sandra, Wagner, Marc, Wattier, Valery, Zaenker, Christophe, Ziegler, François, Zola, Jean-Médard, Centre de Recherches sur l'Action Politique en Europe (ARENES), Université de Rennes (UR)-Institut d'Études Politiques [IEP] - Rennes-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Centre National de la Recherche Scientifique (CNRS), École des Hautes Études en Santé Publique [EHESP] (EHESP), Département Méthodes quantitatives en santé publique (METIS), and Collectif de recherche handicap, autonomie et société inclusive (CoRHASI)

Subjects
Quality of life, Disability, Neurology, Relapsing–remitting multiple sclerosis, Radiological markers, Disease-modifying treatment, Effectiveness, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Neurology (clinical), Tolerability
Abstract

Online ahead of print; International audience; Introduction: It is important to confirm the effectiveness and tolerability of disease-modifying treatments for relapsing-remitting multiple sclerosis (RRMS) in real-world treatment settings. This prospective observational cohort study (VIRGILE) was performed at the request of the French health authorities. The primary objective was to evaluate the effectiveness of fingolimod 0.5 mg in reducing the annualised relapse rate (ARR) in patients with RRMS.Methods: Participating neurologists enrolled all adult patients with RRMS starting fingolimod treatment between 2014 and 2016, who were followed for 3 years. Follow-up consultations took place at the investigator's discretion. The primary outcome measure was the change in ARR at month 24 after fingolimod initiation. Relapses and adverse events were documented at each consultation; disability assessment (EDSS) and magnetic resonance imagery were performed at the investigator's discretion.Results: Of 1055 eligible patients, 633 patients were assessable at month 36; 405 (64.0%) were treated continuously with fingolimod for 3 years. The ARR decreased from 0.92 ± 0.92 at inclusion to 0.31 ± 0.51 at month 24, a significant reduction of 0.58 [95% CI - 0.51 to - 0.65] relapses/year (p < 0.001). Since starting fingolimod, 461 patients (60.9%) remained relapse-free at month 24 and 366 patients (55.5%) at month 36. In multivariate analysis, no previous disease-modifying treatment, number of relapses in the previous year and lower EDSS score at inclusion were associated with a greater on-treatment reduction in ARR. The mean EDSS score remained stable over the course of the study. Sixty-one out of 289 (21.1%) patients presented new radiological signs of disease activity. Treatment-related serious adverse events were lymphopenia (N = 21), bradycardia (N = 19), elevated transaminases (N = 9) and macular oedema (N = 9).Conclusions: The effectiveness and tolerability of fingolimod in everyday clinical practice are consistent with findings of previous phase III studies. Our study highlights the utility of fingolimod for the long-term management of patients with multiple sclerosis.

Published
2022

33. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis

Author

Laplaud, David-Axel, Casey, Romain, Barbin, Laetitia, Debouverie, Marc, De Sèze, Jérôme, Brassat, David, Wiertlewski, Sandrine, Brochet, Bruno, Pelletier, Jean, Vermersch, Patrick, Edan, Gilles, Lebrun-Frenay, Christine, Clavelou, Pierre, Thouvenot, Eric, Camdessanché, Jean-Philippe, Tourbah, Ayman, Stankoff, Bruno, Al Khedr, Abdullatif, Cabre, Philippe, Lubetzki, Catherine, Papeix, Caroline, Berger, Eric, Heinzlef, Olivier, Debroucker, Thomas, Moreau, Thibault, Gout, Olivier, Bourre, Bertrand, Wahab, Abir, Labauge, Pierre, Magy, Laurent, Defer, Gilles, Guennoc, Anne-Marie, Maubeuge, Nicolas, Labeyrie, Céline, Patry, Ivania, Nifle, Chantal, Casez, Olivier, Michel, Laure, Rollot, Fabien, Leray, Emmanuelle, Vukusic, Sandra, Foucher, Yohann, Fontaine, B., Marignier, R., Durand-Dubief, F., Mathey, G., Le Page, E., Peaureaux-Averseng, D., Ouallet, J.C., Ruet, A., Collongues, N., Hautecoeur, P., Zephir, H., Maillard, E., Cohen, M., Derache, N., Branger, P., Ayrignac, X., Carra-Dalliere, C., Fromont, A., Chamard-Witkowski, L., Taithe, F., Moisset, X., Audoin, B., Rico-Lamy, A., Castelnovo, G., Giannesini, C., Fagniez, O., Bensa, C., Gueguen, A., Kasonde, I. Tabellah, De Vilmarest, A., Montcuquet, A., Vaillants, M., Beltran, S., Creange, A., Ayache, S., Abdellaoui, M., Pottier, C., Slesari, I., Deburghraeve, V., Neau, J.P., Servan, J., Pico, F., Henry, C., and Hankiewicz, K.

Published
2019
Full Text
View/download PDF

37. Improvements in Quality of Life Over 2 Years in Patients Treated with Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: Final Analysis of CLARIFY-MS

Author

Solari, Alessandra, Montalban, Xavier, Lechner-Scott, Jeannette, Piehl, Fredrik, Brochet, Bruno, Langdon, Dawn, Hupperts, Raymond, Selmaj, Krzysztof, Havrdova, Eva K., Patti, Francesco, Brieva, Luis, Maida, Eva Maria, Alexandri, Nektaria, Smyk, Andrzej, Nolting, Axel, Keller, Birgit, and on behalf of the CLARIFY-MS Investigators

Published
2023
Full Text
View/download PDF

38. Differential vulnerability of thalamic nuclei in multiple sclerosis

Author

Blyau, Simon, primary, Koubiyr, Ismail, additional, Saranathan, Manojkumar, additional, Coupé, Pierrick, additional, Deloire, Mathilde, additional, Charré-Morin, Julie, additional, Saubusse, Aurore, additional, Zhang, Bei, additional, Rutt, Brian, additional, Dousset, Vincent, additional, Brochet, Bruno, additional, Ruet, Aurélie, additional, and Tourdias, Thomas, additional

Published
2022
Full Text
View/download PDF

39. Signes et symptômes de la sclérose en plaques

Author

Brochet, Bruno, primary, Lebrun-Frénay, Christine, additional, de Sèze, Jérôme, additional, Zéphir, Hélène, additional, Allart, E., additional, Audoin, B., additional, Ayrignac, X., additional, Bensa, C., additional, Blanchard-Dauphin, A., additional, Brassat, D., additional, Carra-Dallière, C., additional, Clavelou, P., additional, Cohen, M., additional, Créange, A., additional, Collongues, N., additional, Debouverie, M., additional, Defer, G., additional, de Sèze, M., additional, Donzé, C., additional, Edan, G., additional, Fromont, A., additional, Gamé, X., additional, Gout, O., additional, Guillon, C., additional, Harand, C., additional, Jenny, B., additional, Labauge, P., additional, Lalive, P.-H., additional, Le Page, E., additional, Marque, P., additional, Michel, L., additional, Moisset, X., additional, Ouallet, J.-C., additional, Outteryck, O., additional, Pelé, F., additional, Pelletier, J., additional, Pittion-Vouyovitch, S., additional, Ramelli, A.-L., additional, Ruet, A., additional, Thouvenot, E., additional, Veillard, D., additional, Vignal-Clermont, C., additional, and Vukusic, S., additional

Published
2017
Full Text
View/download PDF

40. Diagnostics différentiels de la sclérose en plaques

Author

Brochet, Bruno, primary, Lebrun-Frénay, Christine, additional, de Sèze, Jérôme, additional, Zéphir, Hélène, additional, Allart, E., additional, Audoin, B., additional, Ayrignac, X., additional, Bensa, C., additional, Blanchard-Dauphin, A., additional, Brassat, D., additional, Carra-Dallière, C., additional, Clavelou, P., additional, Cohen, M., additional, Créange, A., additional, Collongues, N., additional, Debouverie, M., additional, Defer, G., additional, de Sèze, M., additional, Donzé, C., additional, Edan, G., additional, Fromont, A., additional, Gamé, X., additional, Gout, O., additional, Guillon, C., additional, Harand, C., additional, Jenny, B., additional, Labauge, P., additional, Lalive, P.-H., additional, Le Page, E., additional, Marque, P., additional, Michel, L., additional, Moisset, X., additional, Ouallet, J.-C., additional, Outteryck, O., additional, Pelé, F., additional, Pelletier, J., additional, Pittion-Vouyovitch, S., additional, Ramelli, A.-L., additional, Ruet, A., additional, Thouvenot, E., additional, Veillard, D., additional, Vignal-Clermont, C., additional, and Vukusic, S., additional

Published
2017
Full Text
View/download PDF

41. Thérapeutiques et prise en charge de la sclérose en plaques

Author

Brochet, Bruno, primary, Lebrun-Frénay, Christine, additional, de Sèze, Jérôme, additional, Zéphir, Hélène, additional, Allart, E., additional, Audoin, B., additional, Ayrignac, X., additional, Bensa, C., additional, Blanchard-Dauphin, A., additional, Brassat, D., additional, Carra-Dallière, C., additional, Clavelou, P., additional, Cohen, M., additional, Créange, A., additional, Collongues, N., additional, Debouverie, M., additional, Defer, G., additional, de Sèze, M., additional, Donzé, C., additional, Edan, G., additional, Fromont, A., additional, Gamé, X., additional, Gout, O., additional, Guillon, C., additional, Harand, C., additional, Jenny, B., additional, Labauge, P., additional, Lalive, P.-H., additional, Le Page, E., additional, Marque, P., additional, Michel, L., additional, Moisset, X., additional, Ouallet, J.-C., additional, Outteryck, O., additional, Pelé, F., additional, Pelletier, J., additional, Pittion-Vouyovitch, S., additional, Ramelli, A.-L., additional, Ruet, A., additional, Thouvenot, E., additional, Veillard, D., additional, Vignal-Clermont, C., additional, and Vukusic, S., additional

Published
2017
Full Text
View/download PDF

42. Diagnostic positif de la sclérose en plaques

Author

Brochet, Bruno, primary, Lebrun-Frénay, Christine, additional, de Sèze, Jérôme, additional, Zéphir, Hélène, additional, Allart, E., additional, Audoin, B., additional, Ayrignac, X., additional, Bensa, C., additional, Blanchard-Dauphin, A., additional, Brassat, D., additional, Carra-Dallière, C., additional, Clavelou, P., additional, Cohen, M., additional, Créange, A., additional, Collongues, N., additional, Debouverie, M., additional, Defer, G., additional, de Sèze, M., additional, Donzé, C., additional, Edan, G., additional, Fromont, A., additional, Gamé, X., additional, Gout, O., additional, Guillon, C., additional, Harand, C., additional, Jenny, B., additional, Labauge, P., additional, Lalive, P.-H., additional, Le Page, E., additional, Marque, P., additional, Michel, L., additional, Moisset, X., additional, Ouallet, J.-C., additional, Outteryck, O., additional, Pelé, F., additional, Pelletier, J., additional, Pittion-Vouyovitch, S., additional, Ramelli, A.-L., additional, Ruet, A., additional, Thouvenot, E., additional, Veillard, D., additional, Vignal-Clermont, C., additional, and Vukusic, S., additional

Published
2017
Full Text
View/download PDF

43. Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France

Author

Biotti, Damien, Bonneville, Fabrice, Tournaire, Emilie, Ayrignac, Xavier, Dallière, Clarisse Carra, Mahieu, Laurence, Vignal, Catherine, Dulau, Cecile, Brochet, Bruno, Ruet, Aurélie, Ouallet, Jean-Christophe, Gout, Olivier, Heran, Françoise, Menjot de Champfleur, Nicolas, Tourdias, Thomas, Deneve, Marc, Labauge, Pierre, and Deschamps, Romain

Published
2017
Full Text
View/download PDF

47. sj-docx-1-msj-10.1177_13524585221101470 – Supplemental material for Altered functional brain states predict cognitive decline 5 years after a clinically isolated syndrome

Author

Koubiyr, Ismail, Broeders, Tommy AA, Deloire, Mathilde, Brochet, Bruno, Tourdias, Thomas, Geurts, Jeroen JG, Schoonheim, Menno Michiel, and Ruet, Aurélie

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-docx-1-msj-10.1177_13524585221101470 for Altered functional brain states predict cognitive decline 5 years after a clinically isolated syndrome by Ismail Koubiyr, Tommy AA Broeders, Mathilde Deloire, Bruno Brochet, Thomas Tourdias, Jeroen JG Geurts, Menno Michiel Schoonheim and Aurélie Ruet in Multiple Sclerosis Journal

Published
2022
Full Text
View/download PDF

48. sj-docx-1-msj-10.1177_13524585221114247 – Supplemental material for Differential vulnerability of thalamic nuclei in multiple sclerosis

Author

Blyau, Simon, Koubiyr, Ismail, Saranathan, Manojkumar, Coupé, Pierrick, Deloire, Mathilde, Charré-Morin, Julie, Saubusse, Aurore, Zhang, Bei, Rutt, Brian, Dousset, Vincent, Brochet, Bruno, Ruet, Aurélie, and Tourdias, Thomas

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-docx-1-msj-10.1177_13524585221114247 for Differential vulnerability of thalamic nuclei in multiple sclerosis by Simon Blyau, Ismail Koubiyr, Manojkumar Saranathan, Pierrick Coupé, Mathilde Deloire, Julie Charré-Morin, Aurore Saubusse, Bei Zhang, Brian Rutt, Vincent Dousset, Bruno Brochet, Aurélie Ruet and Thomas Tourdias in Multiple Sclerosis Journal

Published
2022
Full Text
View/download PDF

50. Differential vulnerability of thalamic nuclei in multiple sclerosis.

Author

Blyau, Simon, Koubiyr, Ismail, Saranathan, Manojkumar, Coupé, Pierrick, Deloire, Mathilde, Charré-Morin, Julie, Saubusse, Aurore, Zhang, Bei, Rutt, Brian, Dousset, Vincent, Brochet, Bruno, Ruet, Aurélie, and Tourdias, Thomas

Subjects
THALAMIC nuclei, MULTIPLE sclerosis, COGNITION disorders, COGNITIVE ability, COGNITIVE testing
Abstract

Objectives: Investigating differential vulnerability of thalamic nuclei in multiple sclerosis (MS). Methods: In a secondary analysis of prospectively collected datasets, we pooled 136 patients with MS or clinically isolated syndrome and 71 healthy controls all scanned with conventional 3D-T1 and white-matter-nulled magnetization-prepared rapid gradient echo (WMn-MPRAGE) and tested for cognitive performance. T1-based thalamic segmentation was compared with the reference WMn-MPRAGE method. Volumes of thalamic nuclei were compared according to clinical phenotypes and cognitive profile. Results: T1- and WMn-MPRAGE provided comparable segmentations (0.84 ± 0.13 < volume-similarity-index < 0.95 ± 0.03). Medial and posterior thalamic groups were significantly more affected than anterior and lateral groups. Cognitive impairment related to volume loss of the anterior group. Conclusion: Thalamic nuclei closest to the third ventricle are more affected, with cognitive consequences. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results